Индивидуальный подход в лечении пролактиномы у пациентки с синдромом множественной эндокринной неоплазии 1 типа

Пролактинома и связанная с ней гиперпролактинемия являются одной из основных причин бесплодия. Заболевание может развиваться в рамках синдрома множественной эндокринной неоплазии 1 типа (МЭН1), и ведение таких пациентов может отличаться от лечения спорадических форм. В статье представлен клинический случай планировавшей беременность пациентки с пролактиномой, которая развилась в рамках синдрома МЭН1. Продемонстрирован индивидуальный подход в выборе лечебной тактики, позволивший решить задачу восстановления фертильности.

1. Maiter D, Primeau V. 2012 update in the treatment of prolactinomas. Ann Endocrinol. 2012;73:90–8.

2. Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:273–88.

3. Molitch ME. Endocrinology in pregnancy: management of the pregnant patient with a prolactinoma. Eur J Endocrinol. 2015;172:R205–13.

4. Мельниченко Г.А., Дзеранова Л.К., Пигарова Е.А., Воротникова С.Ю., Рожинская Л.Я., Дедов И.И. Федеральные клинические рекомендации по клинике, диагностике, дифференциальной диагностике и методам лечения гиперпролактинемии. Проблемы эндокринологии. 2013;59(6):19–26.

5. Akkus G, Karagun B, Yaldız HN, et al. Outcomes of surgical and/or medical treatment in patients with prolactinomas during long-term follow-up: a retrospective single-centre study. Horm Mol Biol Clin Investig. 2020;17;42(2):153–157.

6. Giusti F, Cianferotti L, Boaretto F, et al. Multiple endocrine neoplasia syndrome type 1: institution, management, and data analysis of a nationwide multicenter patient database. Endocrine. 2017;58(2):349–359.

7. Brandi ML, Agarwal SK, Perrier ND, et al. Multiple Endocrine Neoplasia Type 1: Latest Insights. Endocr Rev. 2021;42(2):133–170.

8. Dreijerink KM, Goudet P, Burgess JR, et al. Breast-cancer predisposition in multiple endocrine neoplasia type 1. N Engl J Med. 2014;371(6):583–584.

9. Tepede AA, Welch J, Lee M, et al. 18F-FDOPA PET/CT accurately identifies MEN1-associated pheochromocytoma. Endocrinol Diab Metab. 2020;2020:19-0156.

10. Trouillas J, Labat-Moleur F, Sturm N, et al. Pituitary tumors and hyperplasia in multiple endocrine neoplasia type 1 syndrome (MEN1): a case-control study in a series of 77 patients versus 2509 non-MEN1 patients. Am J Surg Pathol. 2008;32(4):534–43.

11. Valea A, Sandru F, Petca A, et al. Aggressive prolactinoma. Exp Ther Med. 2022;23(1):74.

12. Goudet P, Murat A, Binquet C, et al. Risk factors and causes of death in MEN1 disease. A GTE (Groupe d’Etude des Tumeurs Endocrines) cohort study among 758 patients. World J Surg. 2010;34(2):249–255.

13. Goudet P, Dalac A, Le Bras M, et al. MEN1 disease occurring before 21 years old: a 160-patient cohort study from the Groupe d’étude des Tumeurs Endocrines. J Clin Endocrinol Metab. 2015;100(4):1568-1577.

14. Vannucci L, Marini F, Giusti F, et al. MEN1 in children and adolescents: Data from patients of a regional referral center for hereditary endocrine tumors. Endocrine. 2018 Feb;59(2):438–448.

15. Daglar HK, Kirbas A, Biberoglu E, et al. Management of a multiple endocrine neoplasia type 1 during pregnancy: a case report and review of the literature. J Exp Ther Oncol. 2016;11(3):217–220.

16. Mistry M, Gupta M, Kaler M. Pregnancy in multiple endocrine neoplasia type 1 equals multiple complications. Obstet Med. 2014;7(3):123–125.

17. Thakker RV, Newey PJ, Walls GV, et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab. 2012;97(9):2990– 3011.

18. Stratakis CA, Tichomirowa MA, Boikos S, et al. The role of germline AIP, MEN1, PRKAR1A, CDKN1B and CDKN2C mutations in causing pituitary adenomas in a large cohort of children, adolescents, and patients with genetic syndromes. Clin Genet. 2010;78(5):457–463.

19. Salenave S, Ancelle D, Bahougne T, et al. Macroprolactinomas in children and adolescents: factors associated with the response to treatment in 77 patients. J Clin Endocrinol Metab. 2015;100(3):1177– 1186.

20. Park K, Park KH, Park HR, et al. Long-term Outcome of Microscopic Transsphenoidal Surgery for Prolactinomas as an Alternative to Dopamine Agonists. J Korean Med Sci. 2021;36(15):e97.

21. Zamanipoor Najafabadi AH, Zandbergen IM, de Vries F, et al. Surgery as a Viable Alternative FirstLine Treatment for Prolactinoma Patients. A Systematic Review and Meta-Analysis. J Clin Endocrinol Metab. 2020;105(3):e32–41.

22. Maiter D. Prolactinoma and pregnancy: From the wish of conception to lactation. Ann Endocrinol (Paris). 2016;77(2):128–34.